[宫癌的最新药物治疗方法]
Motoko Fujisaki1, Koji Matsumoto
1Division of Medical Oncology, Hyogo Cancer Center.
Gan to kagaku ryoho. Cancer & chemotherapy
|December 24, 2025
概括
像免疫检查点抑制剂 (ICI) 和抗体药物联合体 (ADC) 这样的新疗法正在改变宫癌的治疗. 这些进展为晚期和复发性宫癌患者提供了更好的生存率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药物开发 药物开发
背景情况:
- 宫癌是一个重大的全球健康挑战,特别是在晚期或复发阶段.
- 像化疗放射治疗 (CRT) 这样的传统治疗对这些患者群体有局限性.
研究的目的:
- 总结最近宫癌治疗的突破,重点关注免疫检查点抑制剂 (ICI) 和抗体-药物联合体 (ADC).
- 突出新疗法对临床指南和未来研究方向的影响.
主要方法:
- 对关键临床试验的审查,包括KEYNOTE-826,KEYNOTE-A18和innovaTV 301.
- 对更新的治疗指南进行分析 (NCCN v1,2025;ESMO/ESGO/ESTRO).
主要成果:
- 布罗利祖马布与化疗相结合,为复发性/转移性宫癌建立了新的一线标准.
- 布罗利祖马布与CRT一起显著改善了局部晚期疾病的存活率.
- 提索托马布维多丁 (tisotumab vedotin) 在先前治疗的复发性/转移性子宫癌中显示出改善的整体存活率.
结论:
- 目前的指导方针现在包括ICI和ADC用于各种宫癌的设置.
- 未来的研究重点是生物标志物,瘤微环境和个性化治疗的组合策略.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.1K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
相关概念视频
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines
926
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
926
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
564
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
564
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
